BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27

• Press Releases

  Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

  June 5, 2025

   · 

  4 min read
• Press Releases

  Seyltx Announces Positive Non-Human Primate (NHP) and Additional In Vivo Data for its Centrally Acting Inhibitor of GluN2B in Chronic Cough, Paving the Way for Optimized Later-Stage Phase 2 Trials

  June 5, 2025

   · 

  5 min read
• Press Releases

  LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

  June 5, 2025

   · 

  5 min read
• Press Releases

  Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management

  June 5, 2025

   · 

  7 min read
• Press Releases

  Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough

  June 5, 2025

   · 

  5 min read
• Press Releases

  Outset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

  June 5, 2025

   · 

  1 min read
• Press Releases

  Merz Aesthetics® Receives Approval from Health Canada for RADIESSE® as an Aesthetic Injectable for the Treatment of Moderate Wrinkles in the Décolleté Area

  June 5, 2025

   · 

  4 min read
• Press Releases

  Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

  June 5, 2025

   · 

  2 min read
• Press Releases

  Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

  June 5, 2025

   · 

  1 min read
• Press Releases

  Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

  June 5, 2025

   · 

  9 min read